Actinium zadavotide guraxetan AC-225 clinical trials
Also written FPI-2265.
How each study uses actinium zadavotide guraxetan AC-225 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the actinium zadavotide guraxetan AC-225 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- FPI-2265
- 4
Studies by the year they started
4 studies that test it; most in 2021 (1)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Radiopharmaceuticals source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test actinium zadavotide guraxetan AC-225.
- Dec 2026FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)Phase 2 · Fusion Pharmaceuticals Inc.
- May 2027FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)Phase 2 · Fusion Pharmaceuticals Inc.
Studies
Open first, then newest update. How each study uses actinium zadavotide guraxetan AC-225 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate CancerRecruitingPhase 1/2AstraZenecaNCT07590934Written as AZD2265 (FPI-2265)
- FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)Active, not recruitingPhase 2Fusion Pharmaceuticals Inc.NCT06909825Written as FPI-2265
- FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)Active, not recruitingPhase 2Fusion Pharmaceuticals Inc.NCT06402331Written as FPI-2265
- Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).Active, not recruitingPhase 2Fusion Pharmaceuticals Inc.NCT05219500Written as FPI-2265
Codes
What other systems call actinium zadavotide guraxetan AC-225 · ClinicalTrials.gg INT018339
- UNII (FDA) WAW9659ZJDACTINIUM ZADAVOTIDE GURAXETAN AC-225One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | WAW9659ZJD | ACTINIUM ZADAVOTIDE GURAXETAN AC-225 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.